Menu Back to Meeting-Details

Oligonucleotide-Based Therapeutics Conference Call for Poster Abstracts

4/25/2022 8:00:00 AM - 4/27/2022 12:30:00 PM

Bethesda North Marriott Hotel and Conference Center 5701 Marinelli Road, North Bethesda, MD 20852 USA


DIA/FDA Oligonucleotide-Based Therapeutics Conference
Call for Poster Abstracts

Read Abstract Details | Submit

Abstract Submission Deadline: The week of January 14, 2022

Notification: Week of February 7, 2022

Forum Dates: April 25-27

Location: North Bethesda, MD

Questions: Contact Jessica.Roman@DIAglobal.org

Poster Submission Overview and Topics

The DIA/FDA Oligonucleotide-Based Therapeutics Conference Program Committee welcomes abstracts based on the primary interest area topics in support of the following core interest areas: Nonclinical, clinical, and CMC.

Nonclinical Track

The nonclinical sessions are designed to provide updates and discussion on recent advancements in nonclinical development of oligonucleotide therapeutics. All mechanisms of RNA targeting therapeutics will be represented with a particular interest in delivery to nonhepatic tissues.

Clinical Development Track

These sessions will provide updates on the recent progress made with oligonucleotides in the clinic. Programs in various stages of development will highlight the challenges faced, lessons learned, and offer potential solutions and innovative ideas for clinical development of oligonucleotide therapeutics.

Chemistry, Manufacturing, and Controls (CMC) Track

The CMC track will cover a wide range of current oligonucleotide science and feature expert speakers from industry and regulatory agencies.

Poster submissions may include the following oligonucleotide-related topics:

  • Assay Development and Optimization
  • Clinical Pharmacology, including Oligonucleotide ADME
  • Clinical Safety
  • Formulations
  • Hot Topics in Oligonucleotide Research
  • Impurities
  • Manufacturing
  • Nonclinical Efficacy Models
  • Toxicology, Including Updates in Oligo Toxicology (Clinical and Nonclinical)
  • Novel Mechanisms for Intervention
  • Novel Oligonucleotide Therapeutics
  • Oligonucleotide Conjugation and Tissue Targeting
  • Regulatory Affairs, Including Oligonucleotide Regulatory Guidance
  • Oligonucleotide Therapeutics for:
    • Rare Diseases
    • Immuno-oncology
    • Metabolic and Cardiovascular Diseases
    • Neuromuscular Conditions
  • Targeting and Delivery, Including Target Identification Screening Methods (Discovery)
  • Translational Experience